The prognostic significance of myelonecrosis after induction therapy in acute leukemia

✍ Scribed by Peter A. Cassileth; John S. J. Brooks

• Publisher: John Wiley and Sons
• Year: 1987
• Tongue: English
• Weight: 313 KB
• Volume: 60
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(19871115)60:10<2363::aid-cncr2820601002>3.0.co;2-5

✦ Synopsis

Myelonecrosis is a rare antemortem finding in acute leukemia and its clinical significance is uncertain. The clinical events in nine patients with acute leukemia whose bone marrow biopsies after induction therapy revealed myelonecrosis were reviewed. No patient gained a complete remission and four patients achieved a partial remission. The median duration of survival was 2 months (range, <1 month to 8.5 months) from the start of therapy. Myelonecrosis after induction therapy in acute leukemia indicates a very poor prognosis.